vs
BillionToOne, Inc.（BLLN）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
RESOURCES CONNECTION, INC.的季度营收约是BillionToOne, Inc.的1.4倍（$117.7M vs $83.5M），BillionToOne, Inc.净利率更高（6.8% vs -10.8%，领先17.6%），BillionToOne, Inc.同比增速更快（117.4% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $6.5M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
BLLN vs RGP — 直观对比
营收规模更大
RGP
是对方的1.4倍
$83.5M
营收增速更快
BLLN
高出136.6%
-19.2%
净利率更高
BLLN
高出17.6%
-10.8%
自由现金流更多
RGP
多$9.1M
$6.5M
损益表 — Q3 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $117.7M |
| 净利润 | $5.7M | $-12.7M |
| 毛利率 | 69.9% | 37.1% |
| 营业利润率 | 11.5% | -10.3% |
| 净利率 | 6.8% | -10.8% |
| 营收同比 | 117.4% | -19.2% |
| 净利润同比 | 138.3% | 81.6% |
| 每股收益（稀释后） | $0.10 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNRGP
| Q4 25 | — | $117.7M | ||
| Q3 25 | $83.5M | $120.2M | ||
| Q2 25 | — | $139.3M | ||
| Q1 25 | — | $129.4M | ||
| Q4 24 | — | $145.6M | ||
| Q3 24 | $38.4M | $136.9M | ||
| Q2 24 | — | $148.2M | ||
| Q1 24 | — | $151.3M |
净利润BLLNRGP
| Q4 25 | — | $-12.7M | ||
| Q3 25 | $5.7M | $-2.4M | ||
| Q2 25 | — | $-73.3M | ||
| Q1 25 | — | $-44.1M | ||
| Q4 24 | — | $-68.7M | ||
| Q3 24 | $-14.9M | $-5.7M | ||
| Q2 24 | — | $10.5M | ||
| Q1 24 | — | $2.5M |
毛利率BLLNRGP
| Q4 25 | — | 37.1% | ||
| Q3 25 | 69.9% | 39.5% | ||
| Q2 25 | — | 40.2% | ||
| Q1 25 | — | 35.1% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | 52.6% | 36.5% | ||
| Q2 24 | — | 40.2% | ||
| Q1 24 | — | 37.0% |
营业利润率BLLNRGP
| Q4 25 | — | -10.3% | ||
| Q3 25 | 11.5% | -1.7% | ||
| Q2 25 | — | -47.0% | ||
| Q1 25 | — | -38.4% | ||
| Q4 24 | — | -52.7% | ||
| Q3 24 | -32.9% | -3.5% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | 2.8% |
净利率BLLNRGP
| Q4 25 | — | -10.8% | ||
| Q3 25 | 6.8% | -2.0% | ||
| Q2 25 | — | -52.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -47.2% | ||
| Q3 24 | -38.8% | -4.2% | ||
| Q2 24 | — | 7.1% | ||
| Q1 24 | — | 1.7% |
每股收益（稀释后）BLLNRGP
| Q4 25 | — | $-0.38 | ||
| Q3 25 | $0.10 | $-0.07 | ||
| Q2 25 | — | $-2.21 | ||
| Q1 25 | — | $-1.34 | ||
| Q4 24 | — | $-2.08 | ||
| Q3 24 | $-1.47 | $-0.17 | ||
| Q2 24 | — | $0.31 | ||
| Q1 24 | — | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $89.8M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $194.6M |
| 总资产 | $327.5M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNRGP
| Q4 25 | — | $89.8M | ||
| Q3 25 | $195.2M | $77.5M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $72.5M | ||
| Q4 24 | — | $78.2M | ||
| Q3 24 | — | $89.6M | ||
| Q2 24 | — | $108.9M | ||
| Q1 24 | — | $113.8M |
总债务BLLNRGP
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNRGP
| Q4 25 | — | $194.6M | ||
| Q3 25 | $-239.5M | $206.4M | ||
| Q2 25 | — | $207.1M | ||
| Q1 25 | — | $277.8M | ||
| Q4 24 | — | $325.7M | ||
| Q3 24 | $-242.9M | $407.2M | ||
| Q2 24 | — | $418.8M | ||
| Q1 24 | — | $414.9M |
总资产BLLNRGP
| Q4 25 | — | $289.3M | ||
| Q3 25 | $327.5M | $287.2M | ||
| Q2 25 | — | $304.7M | ||
| Q1 25 | — | $375.6M | ||
| Q4 24 | — | $424.9M | ||
| Q3 24 | — | $512.9M | ||
| Q2 24 | — | $510.9M | ||
| Q1 24 | — | $523.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $15.6M |
| 自由现金流率自由现金流/营收 | 7.7% | 13.2% |
| 资本支出强度资本支出/营收 | 8.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $24.3M |
8季度趋势，按日历期对齐
经营现金流BLLNRGP
| Q4 25 | — | $15.9M | ||
| Q3 25 | $13.8M | $-7.8M | ||
| Q2 25 | — | $16.8M | ||
| Q1 25 | — | $659.0K | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | — | $-309.0K | ||
| Q2 24 | — | $3.2M | ||
| Q1 24 | — | $20.5M |
自由现金流BLLNRGP
| Q4 25 | — | $15.6M | ||
| Q3 25 | $6.5M | $-8.0M | ||
| Q2 25 | — | $16.5M | ||
| Q1 25 | — | $238.0K | ||
| Q4 24 | — | $61.0K | ||
| Q3 24 | — | $-575.0K | ||
| Q2 24 | — | $3.0M | ||
| Q1 24 | — | $20.4M |
自由现金流率BLLNRGP
| Q4 25 | — | 13.2% | ||
| Q3 25 | 7.7% | -6.6% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | -0.4% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 13.5% |
资本支出强度BLLNRGP
| Q4 25 | — | 0.3% | ||
| Q3 25 | 8.8% | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
现金转化率BLLNRGP
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
